Acadia Pharmaceuticals Files 8-K Report
Ticker: ACAD · Form: 8-K · Filed: Apr 16, 2025 · CIK: 1070494
| Field | Detail |
|---|---|
| Company | Acadia Pharmaceuticals Inc (ACAD) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financial-statements, corporate-governance
Related Tickers: ACAD
TL;DR
ACAD filed an 8-K for admin updates and financials. Nothing major disclosed yet.
AI Summary
On April 15, 2025, Acadia Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns amendments to its Articles of Incorporation or Bylaws and the submission of Financial Statements and Exhibits. No specific financial figures or significant business events were detailed in the provided excerpt.
Why It Matters
This filing indicates administrative updates and the submission of financial documents, which are standard procedures for public companies to maintain regulatory compliance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for administrative and financial document submission, not indicating any immediate material changes or risks.
Key Players & Entities
- ACADIA PHARMACEUTICALS INC (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- 000-50768 (filing_id) — SEC File Number
- 06-1376651 (tax_id) — IRS Employer Identification No.
- 12830 El Camino Real , Suite 400 (address) — Principal Executive Offices
- San Diego (city) — Principal Executive Offices
- California (state) — Principal Executive Offices
- 92130 (zip_code) — Principal Executive Offices
- (858) 558-2871 (phone_number) — Registrant's Telephone Number
- April 15, 2025 (date) — Date of earliest event reported
FAQ
What specific amendments were made to Acadia Pharmaceuticals Inc.'s Articles of Incorporation or Bylaws?
The provided excerpt of the 8-K filing does not specify the details of the amendments made to the Articles of Incorporation or Bylaws.
What financial statements and exhibits were filed with this 8-K report?
The excerpt states that Financial Statements and Exhibits were filed, but does not list the specific documents included.
What is the primary purpose of this 8-K filing for Acadia Pharmaceuticals Inc. on April 15, 2025?
The primary purpose is to report amendments to its Articles of Incorporation or Bylaws and to file Financial Statements and Exhibits.
Is there any information about recent business developments or material events in this filing?
Based on the provided text, this 8-K filing focuses on administrative and document submission items, and does not detail specific recent business developments or material events.
What is Acadia Pharmaceuticals Inc.'s fiscal year end?
Acadia Pharmaceuticals Inc.'s fiscal year ends on December 31 (1231).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 16, 2025 regarding ACADIA PHARMACEUTICALS INC (ACAD).